Bin Wu
Founder & Chief Executive Officer Cytodigm
Dr. Bin Wu is the Founder and CEO of Cytodigm. He founded Phosphorex in 2005. As the President and CEO, he led Phosphorex to become an industry leader in drug delivery, providing innovative technologies and development services to the pharmaceutical and biotech industry before it was acquired by Ampersand Capital Partners in 2022. Dr. Wu has over 20 years of experience in biodegradable polymeric microspheres, lipid and polymer nanoparticles, and targeted delivery of small molecules, peptides, proteins, and nucleic acids. He is the inventor of over 20 US patents and 30 international PCT applications. Dr. Wu holds a Ph.D. in Polymer Chemistry from the University of Massachusetts Amherst.
Seminars
As in vivo therapies expand beyond the liver, enabling extrahepatic delivery is essential to unlock new indications. This workshop explores strategies to reach CNS, bone marrow, lung, kidney and immune cells using approaches highlighted across the field.
This workshop will:
- Compare extrahepatic delivery strategies including localized routes, passive targeting, antibody- or bispecific mediated attachment, and next-generation LNP/viral designs
- Outline how teams evaluate biodistribution, species differences and regulatory expectations for non-hepatic targeting
- Provide a framework to select and validate delivery approaches that broaden the treatable disease landscape
- Share practical considerations to reduce CMC burden while achieving precise extrahepatic tropism
